BLUE-C is one of the largest clinical trials assessing a colorectal cancer screening test, with more than 20,000 adults 40 years of age and older. The results show that our next-generation Cologuard® test met all study endpoints1.Next-gen Cologuard in BLUE-C study Specificity including ...
Exact Sciences董事长兼首席执行官Kevin Conroy表示:“Cologuard 是非侵入性癌症检测领域的突破性创新,下一代Cologuard将带来新的性能标准。目前我们正在利用深入的科学见解、先进的技术以及十多年的研究和开发经验,助力开发灵敏度更高且能够显著改善假阳性率的结直肠癌检测测试。” 据悉,Exact Sciences计划在2023年底前完...
For women diagnosed withearly-stage, estrogen-receptor-positive, HER2-negative invasive breast cancer,Exact Sciences offers the Oncotype DX Breast Recurrence Score® test to help patients and their doctors understand what treatment options are right for them, including if they are likely to benefit ...
Exact Sciences won Food and Drug Administration approval on Friday for an improved version of a stool-based screening test for colon cancer that should result in fewer cancer-free patients receiving unnecessary follow-up colonoscopies. The FDA approved the test, Cologuard Plus, ...
To our knowledge, this will be the first RCT to examine whether combining exercise with ACT produces greater benefit for patients with chronic pain, compared to a standalone supervised exercise programme. Trial registration www.ClinicalTrials.gov, ID: NCT03050528. Registered on 13 February 2017.Pee...
摘要: The article reports on Exact Sciences' completion of its underwritten public offering of common stock. The transaction, priced at 6 U.S. dollars per share, sold a total of 11,500,000 shares of common stock due to the exercise in full of the overallotment option. This amounted to ...
A real clinical trial to treat psoriasis is used to illustrate the application of the considered exact approaches.doi:10.1007/s43441-019-00070-wShan, GuogenSchool of Community Health Sciences, University of Nevada Las Vegas, Las Vegas, USADodge-Francis, Carolee...
The data could also arise in randomized clinical trials in which each subject is assigned randomly to one of two treatments. The goal is to test whether the treatments differ with respect to their response distributions. Here it is not necessary to make any assumptions about the underlying ...
LoginNow Filed under Business News Molecular Diagnostics Proteomics & Protein Research JP Morgan Healthcare Conference North America Bruker Exact Sciences Qiagen Europe Neogenomics Veracyte Guardant Health We recommend BreakingNews Sysmex Inostics Gets NYS CLEP Approval for Clinical Trial-Use Liqui...
The protein fractions were injected into an API-300 LC/MS/MS (PerkinElmer Life Sciences Sciex, Waltham, Massachusetts, USA) to determine the mass and homogeneity as described previously31. Analyst software 1.4.1 was used to analyze and deconvolute the raw mass data. N-terminal sequencing. ...